Cytomegalovirus (CMV) causes serious infection in individuals with deficient T cell immunity. In acquired immunodeficiency syndrome, the retina is a major site of progressive infection, despite the availability of therapy that targets CMV. The administration of highly active antiretroviral therapy to suppress human immunodeficiency virus frequently results in resolution of CMV retinitis, but this may be complicated by ocular inflammation termed "immune recovery uveitis" (IRU). To provide insight into the pathogenesis of IRU, the phenotype and specificity of intraocular T cells in a single patient were analyzed. The T cell infiltrate consisted of a diverse population of CD8(+) CMV-specific T cells, but only a minority of these T cells recognized the CMV phosphoprotein 65 and immediate early protein 1, which have been considered major targets of the host response. These results imply that reconstitution of CMV-specific T cells plays a role in IRU and suggest that the specificity of T cells engaged in the control of CMV at local sites of reactivation may be broad.

Download full-text PDF

Source
http://dx.doi.org/10.1086/342044DOI Listing

Publication Analysis

Top Keywords

cmv-specific cells
8
cmv
5
cells
5
association immune
4
immune recovery
4
recovery uveitis
4
uveitis diverse
4
diverse intraocular
4
intraocular cytomegalovirus-specific
4
cytomegalovirus-specific cytotoxic
4

Similar Publications

Background: Kidney transplant (KT) recipients at intermediate risk for cytomegalovirus (CMV) infection constitute a potential target for individualized prevention strategies informed by the CMV-specific cell-mediated immunity (CMV-CMI). The optimal method for the functional assessment of CMV-CMI in this group remains unclear.

Methods: We included 74 CMV-seropositive KT recipients that did not receive T-cell-depleting induction and were managed by preemptive therapy.

View Article and Find Full Text PDF

Acute myeloid leukemia (AML) that is relapsed and/or refractory post-allogeneic hematopoietic cell transplantation (HCT) is usually fatal. In a prior study, we demonstrated that AML relapse in high-risk patients was prevented by post-HCT immunotherapy with Epstein-Barr virus (EBV)-specific donor CD8 T cells engineered to express a high-affinity Wilms Tumor Antigen 1 (WT1)-specific T-cell receptor (T). However, in the present study, infusion of EBV- or Cytomegalovirus (CMV)-specific T did not clearly improve outcomes in fifteen patients with active disease post-HCT.

View Article and Find Full Text PDF
Article Synopsis
  • CMV reactivation is a significant health issue for patients who have undergone stem cell or organ transplants, leading to increased risks of illness and death.
  • Three CMV-specific Fab-antibodies (A6, C1, C7) have been developed to bind to particular MHC molecules, showing effectiveness in targeting and destroying CMV-infected cells, especially when used in combination with natural killer (NK) cells.
  • The TCR-like antibodies also demonstrated the ability to activate neutrophils to kill target cells, offering a promising treatment option for patients experiencing or at risk of CMV reactivation, with a broader potential patient application than previous methods.
View Article and Find Full Text PDF
Article Synopsis
  • γδ T-cells play a crucial role in immune surveillance following HLA-Haploidentical Stem Cell Transplantation (haplo-HSCT), especially in pediatric patients.
  • A study showed that a specific subset of Vδ2 T-cells is associated with better antiviral protection, as these cells were more prevalent in patients who did not experience viral reactivation.
  • The research highlights how Vδ2 T-cells can inhibit CMV replication and enhance the immune response, suggesting their potential use in immunotherapy post-transplantation to combat both infections and tumors.
View Article and Find Full Text PDF

Human CMV, regularly reactivated by simple triggers, results in asymptomatic viral shedding, powerful cellular immune responses, and memory inflation. Immunocompetent individuals benefit from a robust immune response, which aids in viral management without causing clinically significant illness; however, immunodeficient individuals are always at a higher risk of CMV reactivation and disease. Hematopoietic stem cell transplant (HSCT) recipients are consistently at higher risk of CMV reactivation and clinically significant CMV illness due to primary disease, immunosuppression, and graft vs.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!